TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27956826

Group type: EXPERIMENTAL
Intervention: Trimebutine 200 mg three times daily half an hour before meals
Number of subjects: 40

Group type: COMPARATOR
Intervention: Probiotics (60 mg per-tablet of Lactobacillus acidophilus and Bifidobacterium infantis), 2×/d, 1 hour after meals
Number of subjects: 40
Study: 23602614

Group type: EXPERIMENTAL
Intervention: Orange juice (500 mL daily)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Hesperidin (292 mg in a capsule with isocaloric control beverage)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (isocaloric control beverage)
Number of subjects: 24
Study: 22076245

Group type: EXPERIMENTAL
Intervention: Ecstasy (MDMA 100 mg) and Alcohol (BAC 0.5‰)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alcohol (BAC 0.3‰, 0.5‰, and 0.8‰)
Number of subjects: 0
Study: 20809276

Group type: EXPERIMENTAL
Intervention: Clinical pharmacist discharge service
Number of subjects: 85

Group type: COMPARATOR
Intervention: Regular care by doctors and nurses (Control)
Number of subjects: 85
Study: 18547954

Group type: EXPERIMENTAL
Intervention: 15 IU/m(2)/week
Number of subjects: 49

Group type: COMPARATOR
Intervention: 30 IU/m(2)/week
Number of subjects: 49
Study: 15964889

Group type: EXPERIMENTAL
Intervention: Simulator-based instruction (Group S)
Number of subjects: 234

Group type: COMPARATOR
Intervention: No simulator instruction (Group C)
Number of subjects: 234
Study: 14516875

Group type: EXPERIMENTAL
Intervention: Abciximab
Number of subjects: 2082
Study: 10382579

Group type: EXPERIMENTAL
Intervention: ACHX gum (liquorice flavoured CHX/X)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: BCHX gum (chocolate mint flavoured CHX/X)
Number of subjects: 8

Group type: COMPARATOR
Intervention: X gum (liquorice flavoured X gum)
Number of subjects: 8
Study: 8911176

Group type: EXPERIMENTAL
Intervention: MR imaging
Number of subjects: 29

Group type: COMPARATOR
Intervention: Cineangiography
Number of subjects: 29
Study: 1873888

Group type: EXPERIMENTAL
Intervention: Albendazole 8-10 mg/kg.d, 2-3 times a day for 30 days, followed by a 10-day break, continued for 3-12 months (Group I, 72 cases)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Albendazole 15.6-20 mg/kg.d for 14 days, every two weeks with a 10-day interval for 3-6 months (Group II, 8 cases)
Number of subjects: 80
Study: 6224046

Group type: EXPERIMENTAL
Intervention: 1500 mg MPA p.o. daily
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 500 mg MPA i.m. on 5 days per week
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Cortisol suppression
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hormone profile monitoring (cortisol and prolactin)
Number of subjects: 51
Study: 31656165

Group type: EXPERIMENTAL
Intervention: Retroclavicular block (RCB)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Infraclavicular block (ICB)
Number of subjects: 109
Study: 29785925

Group type: EXPERIMENTAL
Intervention: 24-single-nucleotide polymorphism (SNP) Barcoding Assay
Number of subjects: 0

Group type: COMPARATOR
Intervention: msp‐1 and msp‐2 genotyping
Number of subjects: 0
Study: 26942907

Group type: EXPERIMENTAL
Intervention: Deprescribing intervention (n = 47) - planned cessation of non-beneficial medicines
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (control group, n = 48)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Deprescribing intervention
Number of subjects: 95

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 95
Study: 24268704

Group type: EXPERIMENTAL
Intervention: AMH assessment for group A1
Number of subjects: 4917

Group type: COMPARATOR
Intervention: Control group B (including B1 and B2)
Number of subjects: 4917
Study: 22873717

Group type: EXPERIMENTAL
Intervention: Multi-level, multi-intervention strategies for injury and violence prevention
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Process evaluation focusing on community engagement
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Impact evaluation considering risk and protective factors
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Outcome evaluation examining overall effectiveness of interventions
Number of subjects: 24
Study: 20635179

Group type: EXPERIMENTAL
Intervention: High dose of alcohol (0.8 g/kg)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Low dose of alcohol (0.4 g/kg)
Number of subjects: 138

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 138
Study: 17264200

Group type: EXPERIMENTAL
Intervention: Ethics review process (ERP) duration
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Ethics review process (ERP) costs
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Administrative effort for primary approval
Number of subjects: 18
Study: 15885983

Group type: EXPERIMENTAL
Intervention: Group CBT
Number of subjects: 85

Group type: COMPARATOR
Intervention: Control (treatment as usual)
Number of subjects: 85
Study: 12195763

Group type: EXPERIMENTAL
Intervention: Amitriptyline 25 mg for 3 days, then 50 mg for 4 days (15 mg and 30 mg for patients over 65 years)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 16
Study: 9674294

Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 70

Group type: COMPARATOR
Intervention: Unfractionated heparin
Number of subjects: 70
Study: 7986242

Group type: EXPERIMENTAL
Intervention: Effervescent tablet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Instant milk drink
Number of subjects: 12

Group type: COMPARATOR
Intervention: Commercial tablet
Number of subjects: 12
Study: 3141891

Group type: EXPERIMENTAL
Intervention: GHRH administered subcutaneously every 3 hours (n = 10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GHRH administered subcutaneously every 3 hours overnight only (n = 10)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GHRH administered by twice daily injections (n = 4)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Extended treatment with GHRH (n = 16)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: GHRH therapy (n = 11 with circulating antibodies)
Number of subjects: 24
Study: 5018311

Group type: EXPERIMENTAL
Intervention: 5% dextrose as diluent for heparin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5% sorbitol as diluent for heparin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 31170481

Group type: EXPERIMENTAL
Intervention: High-intensity interval cycling exercise
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Low intensity continuous cycling exercise
Number of subjects: 13

Group type: COMPARATOR
Intervention: Rest
Number of subjects: 13
Study: 27720838

Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) for 12 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 12 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) for 16 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Elbasvir (50 mg) and Grazoprevir (100 mg) with Ribavirin for 16 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Elbasvir and Grazoprevir for 12 weeks without Ribavirin
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Elbasvir and Grazoprevir for 12 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Elbasvir and Grazoprevir with Ribavirin for 16 weeks
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Adverse events
Number of subjects: 420
Study: 25620198

Group type: EXPERIMENTAL
Intervention: Below-the-knee compression stockings worn during the daytime for 2 weeks
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no compression stockings)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Below-the-knee compression stockings
Number of subjects: 45
Study: 23886139

Group type: EXPERIMENTAL
Intervention: KAI1/CD82 positive protein expression
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: MRP1/CD9 positive protein expression
Number of subjects: 100

Group type: COMPARATOR
Intervention: KAI1/CD82 and MRP1/CD9 expression in LSCC specimens
Number of subjects: 100
Study: 21890778

Group type: EXPERIMENTAL
Intervention: Maraviroc
Number of subjects: 859

Group type: COMPARATOR
Intervention: Efavirenz
Number of subjects: 859

Group type: EXPERIMENTAL
Intervention: Enhanced Sensitivity Trofile Assay (ESTA) for Maraviroc
Number of subjects: 859

Group type: COMPARATOR
Intervention: Enhanced Sensitivity Trofile Assay (ESTA) for Efavirenz
Number of subjects: 859
Study: 19672110

Group type: EXPERIMENTAL
Intervention: Beta-blockers
Number of subjects: 2286

Group type: COMPARATOR
Intervention: No beta-blockers (Control)
Number of subjects: 2286
Study: 17202013

Group type: EXPERIMENTAL
Intervention: Intubating laryngeal mask airway
Number of subjects: 60

Group type: COMPARATOR
Intervention: GlideScope
Number of subjects: 60
Study: 14990402

Group type: EXPERIMENTAL
Intervention: 52.5 mg gel
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: 100 mg gel
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: 150 mg gel
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Film (100 mg)
Number of subjects: 1536

Group type: EXPERIMENTAL
Intervention: Suppository (100 mg)
Number of subjects: 1536

Group type: COMPARATOR
Intervention: All products
Number of subjects: 1536
Study: 11720694

Group type: EXPERIMENTAL
Intervention: Ipsapirone (IPS) 0.5 mg/kg, p.o.
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Ipsapirone (IPS)
Number of subjects: 43
Study: 9257201

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 12.5 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 25 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 50 mg
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Dolasetron mesilate 100 mg
Number of subjects: 281

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 281

Group type: EXPERIMENTAL
Intervention: Dolasetron (all doses)
Number of subjects: 281
Study: 8275620

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide
Number of subjects: 8
Study: 3526900

Group type: EXPERIMENTAL
Intervention: Motrin (ibuprofen)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 29730633

Group type: EXPERIMENTAL
Intervention: GP-endorsed reminder letter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Reminder letter without GP endorsement
Number of subjects: 0
Study: 26525126

Group type: EXPERIMENTAL
Intervention: Local Anaesthesia (LA+)
Number of subjects: 60

Group type: COMPARATOR
Intervention: No Local Anaesthesia (LA-)
Number of subjects: 60
Study: 24225816

Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate (0.3 g·kg‐1BM)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Beta-alanine (6.4 g·day‐1 for 4 weeks, 3.2 g·day‐1 for 1 week)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Cosupplementation with sodium bicarbonate and beta-alanine
Number of subjects: 36
Study: 22807611

Group type: EXPERIMENTAL
Intervention: sumatriptan 50 mg
Number of subjects: 10

Group type: COMPARATOR
Intervention: control condition (test meal alone)
Number of subjects: 10
Study: 19680081

Group type: EXPERIMENTAL
Intervention: Simulation scenarios (roles: team leader, procedure chief, team member)
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Self-reported learning values
Number of subjects: 53

Group type: COMPARATOR
Intervention: Role in the scenario
Number of subjects: 53
Study: 17472478

Group type: EXPERIMENTAL
Intervention: Eclipta alba (3 g/day in encapsulated form)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study: 15590255

Group type: EXPERIMENTAL
Intervention: IVRA with lidocaine and clonidine (1 microg/kg)
Number of subjects: 84

Group type: COMPARATOR
Intervention: IVRA with lidocaine only (normal saline)
Number of subjects: 84
Study: 12217228

Group type: EXPERIMENTAL
Intervention: Posturography
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Conventional EMG
Number of subjects: 13
Study: 8122884

Group type: EXPERIMENTAL
Intervention: Scopolamine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Benztropine
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Glycopyrrolate
Number of subjects: 7
Study: 2563465

Group type: EXPERIMENTAL
Intervention: 3-monthly tympanometry screening and subsequent treatment for OME
Number of subjects: 1439

Group type: COMPARATOR
Intervention: Non-treatment group
Number of subjects: 1439
Study: 802644

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: RO3-4787
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31829085

Group type: EXPERIMENTAL
Intervention: 6-lb dumbbells
Number of subjects: 86

Group type: COMPARATOR
Intervention: Handgrip exercise (squeezing rubber balls)
Number of subjects: 86
Study: 31713296

Group type: EXPERIMENTAL
Intervention: Si-based film group (SiFG)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Si-based film group after sandblasting (SiFSG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Polished group (PG) zirconia
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sandblasted group (SG) zirconia
Number of subjects: 0
Study: 28196255

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (daily tablets containing 15 µg of major allergen Phleum p 5)
Number of subjects: 106

Group type: COMPARATOR
Intervention: Placebo (matched double-placebo injections)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Subcutaneous immunotherapy (monthly injections containing 20 µg of Phleum p 5)
Number of subjects: 106
Study: 25679998

Group type: EXPERIMENTAL
Intervention: HIT (High-Intensity Training)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HIT+VIB18 (High-Intensity Training with 18 Hz Whole-Body Vibration)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: HIT+VIB30 (High-Intensity Training with 30 Hz Whole-Body Vibration)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: VIB30 (30 Hz Whole-Body Vibration)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Conventional HIT
Number of subjects: 33
Study: 23593253

Group type: EXPERIMENTAL
Intervention: Vi capsular polysaccharide vaccine
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ty21a vaccine
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Both vaccines
Number of subjects: 50
Study: 21514731

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Isotonic saline (control)
Number of subjects: 21
Study: 19202155

Group type: EXPERIMENTAL
Intervention: Reperfusion VA bursts
Number of subjects: 128
Study: 16926775

Group type: EXPERIMENTAL
Intervention: saquinavir-SGC/ritonavir (1600 mg/100 mg)
Number of subjects: 171
Study: 15344394

Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg once a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice a day
Number of subjects: 40
Study: 10937611

Group type: EXPERIMENTAL
Intervention: Fluoxetine for 14 weeks followed by placebo for 36 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Fluoxetine for 38 weeks followed by placebo for 12 weeks
Number of subjects: 395

Group type: EXPERIMENTAL
Intervention: Fluoxetine for 50 weeks
Number of subjects: 395

Group type: COMPARATOR
Intervention: Placebo for 50 weeks
Number of subjects: 395
Study: 9018854

Group type: EXPERIMENTAL
Intervention: Sacred music
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Secular music
Number of subjects: 0

Group type: COMPARATOR
Intervention: All music combined
Number of subjects: 0
Study: 8160538

Group type: EXPERIMENTAL
Intervention: gemeprost (Cervagem)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: dinoproston (Cerviprost)
Number of subjects: 40
Study: 3412741

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (MP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Metoclopramide (MTC)
Number of subjects: 0
Study: 30240991

Group type: EXPERIMENTAL
Intervention: autoPSV
Number of subjects: 30

Group type: COMPARATOR
Intervention: convPSV
Number of subjects: 30
Study: 28639551

Group type: EXPERIMENTAL
Intervention: Facet joint injections (FJIs) with local anaesthetic and corticosteroids (at up to six injection sites) plus best usual care (BUC)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Best usual care (BUC) alone
Number of subjects: 26
Study: 24908148

Group type: EXPERIMENTAL
Intervention: Progressive Relaxation (PR)
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Sublingual Diazepam
Number of subjects: 84

Group type: COMPARATOR
Intervention: Control (no treatment intervention)
Number of subjects: 84
Study: 23731674

Group type: EXPERIMENTAL
Intervention: Antiandrogen therapy combined with exercise (AE)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Chemotherapy with exercise (CE)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Antiandrogen therapy without exercise (A)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chemotherapy without exercise (C)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Exercise five times per week (supervised sessions for AE and CE)
Number of subjects: 80
Study: 20890711

Group type: EXPERIMENTAL
Intervention: 150 mmHg external compression
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control forearm (no compression)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 50 mmHg external compression
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 100 mmHg external compression
Number of subjects: 24
Study: 18258423

Group type: EXPERIMENTAL
Intervention: 20 microg formoterol fumarate inhalation solution twice daily plus tiotropium (FFIS/TIO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nebulized placebo twice daily plus tiotropium (PLA/TIO)
Number of subjects: 0
Study: 17069557

Group type: EXPERIMENTAL
Intervention: Suspension (hang-back) recession technique
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional strabismus surgery
Number of subjects: 16
Study: 12925055

Group type: EXPERIMENTAL
Intervention: Atorvastatin 40 mg/day
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 10866909

Group type: EXPERIMENTAL
Intervention: Single injection of 12 mL of 0.75% ropivacaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multiple injections of 4 mL of 0.75% ropivacaine at each muscular twitch
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multiple injections
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single injection
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Single group (n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Multiple group (n=15)
Number of subjects: 30
Study: 9357393

Group type: EXPERIMENTAL
Intervention: Fluconazole 200 mg every 24 hours (from day 11 to day 20) with losartan 100 mg every 24 hours
Number of subjects: 32

Group type: COMPARATOR
Intervention: Eprosartan 300 mg every 12 hours
Number of subjects: 32
Study: 7950612

Group type: EXPERIMENTAL
Intervention: Enalapril
Number of subjects: 100

Group type: COMPARATOR
Intervention: Beta blockers (conventional treatment)
Number of subjects: 100
Study: 2886560

Group type: EXPERIMENTAL
Intervention: 25 mg captopril BID
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: 50 mg captopril BID
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Doubling the dose of captopril (Phase 3)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Captopril plus diuretic (Phase 4)
Number of subjects: 201

Group type: COMPARATOR
Intervention: Control group (beta blocker-diuretic treatment)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Side effects
Number of subjects: 201
Study: 28985586

Group type: EXPERIMENTAL
Intervention: e-SBI
Number of subjects: 981

Group type: COMPARATOR
Intervention: AO
Number of subjects: 981
Study: 27295978

Group type: EXPERIMENTAL
Intervention: Usual care with additional hip strengthening exercises
Number of subjects: 104

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 104
Study: 24841015

Group type: EXPERIMENTAL
Intervention: High single scrotal incision
Number of subjects: 70

Group type: COMPARATOR
Intervention: Classic inguinal approach
Number of subjects: 70
Study: 23380881

Group type: EXPERIMENTAL
Intervention: ACE inhibitors (ACE‐i)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control
Number of subjects: 70
Study: 20826029

Group type: EXPERIMENTAL
Intervention: Actovegin (30 ml daily, 5 days/week) administered from day 1 of radiotherapy for Group 1 (prevention)
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Actovegin (30 ml daily, 5 days/week) administered from the onset of grade 2 mucositis for Group 2 (treatment)
Number of subjects: 156

Group type: COMPARATOR
Intervention: Control group (no Actovegin)
Number of subjects: 156
Study: 18097226

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI), cycles of 12 weeks on/off (408 participants)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Continuous ART (CT; 405 participants)
Number of subjects: 813

Group type: COMPARATOR
Intervention: Continuous ART (CT)
Number of subjects: 813

Group type: EXPERIMENTAL
Intervention: Structured treatment interruption (STI)
Number of subjects: 813
Study: 17260226

Group type: EXPERIMENTAL
Intervention: Tension-free vaginal tape procedure
Number of subjects: 128

Group type: COMPARATOR
Intervention: Laparoscopic mesh colposuspension
Number of subjects: 128
Study: 14738685

Group type: EXPERIMENTAL
Intervention: Tropisetron
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Tropisetron plus droperidol
Number of subjects: 51

Group type: COMPARATOR
Intervention: Alizapride
Number of subjects: 51
Study: 10793384

Group type: EXPERIMENTAL
Intervention: Galvano-ceramic crowns (Auvo Galvano Crown)
Number of subjects: 410

Group type: COMPARATOR
Intervention: Glass-ceramic individual crowns (Dicor)
Number of subjects: 410
Study: 8832443

Group type: EXPERIMENTAL
Intervention: Marked J-wire (Group M, n = 127)
Number of subjects: 303

Group type: COMPARATOR
Intervention: Plain unmarked J-wire (Group UM, n = 176)
Number of subjects: 303
Study: 1431925

Group type: EXPERIMENTAL
Intervention: Thackray polyethylene plug (38 mm, disc-shaped)
Number of subjects: 77

Group type: COMPARATOR
Intervention: Autologous bone plug
Number of subjects: 77

Group type: COMPARATOR
Intervention: Richard polyethylene plug (18.5 mm, bullet-shaped)
Number of subjects: 77